Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report) and increased the price target to $12.00 from $11.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yi Chen’s rating is based on several positive developments for Sensus Healthcare. The company demonstrated significant revenue growth, with a 71% increase in total revenue for the full year 2024, surpassing projections. This growth was partly driven by the increased shipment of SRT systems, including international sales, which exceeded expectations. Additionally, Sensus Healthcare expanded its Fair Deal Agreement revenue-sharing programs, indicating strong interest from prospective customers and potential for recurring revenue.
Furthermore, the company’s strategic initiatives, such as the development of the TransDermal Infusion System and its integration with Sentinel IT capabilities, showcase potential for future growth. The robust cash position of $22.1 million at the end of December 2024 also provides a solid financial foundation. These factors, combined with a projected revenue of $2.75 per share for 2025 and a calculated price target of $12 per share, support Yi Chen’s Buy rating.
In another report released on February 7, Maxim Group also reiterated a Buy rating on the stock with a $14.00 price target.